Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.

Zhou Q, Gallo JM.

Neuro Oncol. 2009 Jun;11(3):301-10. doi: 10.1215/15228517-2008-088. Epub 2008 Oct 29.

2.

Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.

Zhou Q, Guo P, Gallo JM.

Clin Cancer Res. 2008 Mar 1;14(5):1540-9. doi: 10.1158/1078-0432.CCR-07-4544. Erratum in: Clin Cancer Res. 2008 Aug 15;14(16):5308-9.

3.
4.

Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.

Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM.

Cancer Res. 2001 Jul 15;61(14):5491-8.

5.

Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.

Grossman R, Tyler B, Rudek MA, Kim E, Zadnik P, Khan U, Blakeley JO, Pathak AP, Brem H.

Cancer Chemother Pharmacol. 2013 Jul;72(1):93-100. doi: 10.1007/s00280-013-2172-3. Epub 2013 May 7.

6.

Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.

Ningaraj NS, Sankpal UT, Khaitan D, Meister EA, Vats TS.

Cancer Biol Ther. 2009 Oct;8(20):1924-33. Epub 2009 Oct 12.

PMID:
19738431
7.

Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.

Czabanka M, Bruenner J, Parmaksiz G, Broggini T, Topalovic M, Bayerl SH, Auf G, Kremenetskaia I, Nieminen M, Jabouille A, Mueller S, Harms U, Harms C, Koch A, Heppner FL, Vajkoczy P.

Eur J Cancer. 2013 Jun;49(9):2243-52. doi: 10.1016/j.ejca.2013.02.019. Epub 2013 Mar 14.

PMID:
23499430
8.

Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.

Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, Chu F, Backstrom I, Kalra J, Waterhouse D, Yapp DT, Bally MB.

J Control Release. 2015 Dec 28;220(Pt A):348-57. doi: 10.1016/j.jconrel.2015.10.053. Epub 2015 Nov 1.

PMID:
26528901
9.

Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.

Zhou Q, Lv H, Mazloom AR, Xu H, Ma'ayan A, Gallo JM.

J Pharmacol Exp Ther. 2012 Nov;343(2):509-19. doi: 10.1124/jpet.112.196097. Epub 2012 Aug 6.

10.

Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.

Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM.

J Pharmacol Exp Ther. 2007 Apr;321(1):265-75. Epub 2007 Jan 26.

11.
12.

Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.

Hatipoglu G, Hock SW, Weiss R, Fan Z, Sehm T, Ghoochani A, Buchfelder M, Savaskan NE, Eyüpoglu IY.

Cancer Sci. 2015 Feb;106(2):160-70. doi: 10.1111/cas.12580. Epub 2015 Feb 15.

13.

Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.

Dong J, Zhou G, Tang D, Chen Y, Cui B, Dai X, Zhang J, Lan Q, Huang Q.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2079-84. doi: 10.1007/s00432-012-1290-3. Epub 2012 Jul 24.

PMID:
22825126
14.

Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.

Liu HL, Huang CY, Chen JY, Wang HY, Chen PY, Wei KC.

PLoS One. 2014 Dec 9;9(12):e114311. doi: 10.1371/journal.pone.0114311. eCollection 2014.

15.

Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.

Hillman GG, Singh-Gupta V, Zhang H, Al-Bashir AK, Katkuri Y, Li M, Yunker CK, Patel AD, Abrams J, Haacke EM.

Neoplasia. 2009 Sep;11(9):910-20.

16.
17.

Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.

Brem S, Tyler B, Li K, Pradilla G, Legnani F, Caplan J, Brem H.

Cancer Chemother Pharmacol. 2007 Oct;60(5):643-50. Epub 2007 Jan 26.

PMID:
17256133
18.

Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.

Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, Son MJ, Song HS, Shin HJ, Lee DS, Eoh W, Nam DH.

Oncol Rep. 2006 Jul;16(1):33-9.

PMID:
16786120
19.

Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.

Grossman R, Brastianos H, Blakeley JO, Mangraviti A, Lal B, Zadnik P, Hwang L, Wicks RT, Goodwin RC, Brem H, Tyler B.

J Neurooncol. 2014 Jan;116(1):59-65. doi: 10.1007/s11060-013-1268-2. Epub 2013 Nov 2.

20.

The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.

Grossman R, Rudek MA, Brastianos H, Zadnik P, Brem H, Tyler B, Blakeley JO.

Cancer Chemother Pharmacol. 2012 Jul;70(1):129-39. doi: 10.1007/s00280-012-1867-1. Epub 2012 May 27.

Supplemental Content

Support Center